Jindrich Cinatl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jindrich Cinatl has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Roman A. Blaheta
Zentrum der Chirurgie, Klinik für Urologie und Kinderurologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
3 shared publicationsJens‐Uwe Vogel
Institute of Medical Virology, Center of Hygiene, Clinic of J. W. Goethe‐University, Frankfurt am Main, Germany
2 shared publicationsPablo Hernáiz Driever
Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany
2 shared publicationsEveline Weimer
Zentrum der Hygiene, Institut für Medizinische Virologie, Johann Wolfgang Goethe‐Universität, Frankfurt am Main, Germany
1 shared publicationHans Wilhelm Doerr
Zentrum der Hygiene, Institut für Medizinische Virologie, Johann Wolfgang Goethe‐Universität, Frankfurt am Main, Germany
1 shared publicationHerman O. Gümbel
Zentrum für Augenheilkunde, Johann Wolfgang Goethe‐Universität, Frankfurt am Main, Germany
1 shared publication
Latest Publications
- 6 January 2005
- Published by Wiley in Medicinal Research Reviews
- Vol. 25 (4) , 383-397
Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies
The short chain fatty acid valproic acid (VPA) and VPA‐analogs modulate the biology of diverse tumor cell entities by inducing differentiation, inhibiting proliferation, increasing apoptosis, and immunogenicity and by decreasing metastatic and angiogenetic potential. This review updates an earlier one in 2002, reflecting the interest in VPA as a potent anticancer drug. A number of in vitro studies show that the types of known tumor cells susceptible to VPA is steadily increasing. Of special note is the strong antineoplastic activity of VPA in chemoresistant cancer cells. A novel and promising approach is combining VPA with other drugs to achieve a broad therapeutic index. Clinical studies are underway and the preliminary results indicate that VPA alone or in combination offers a promising avenue of treatment, both in solid and hematopoetic malignancies.
- 6 January 2005
- Published by Wiley in Medicinal Research Reviews
- Vol. 25 (4) , 383-397
Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies
The short chain fatty acid valproic acid (VPA) and VPA‐analogs modulate the biology of diverse tumor cell entities by inducing differentiation, inhibiting proliferation, increasing apoptosis, and immunogenicity and by decreasing metastatic and angiogenetic potential. This review updates an earlier one in 2002, reflecting the interest in VPA as a potent anticancer drug. A number of in vitro studies show that the types of known tumor cells susceptible to VPA is steadily increasing. Of special note is the strong antineoplastic activity of VPA in chemoresistant cancer cells. A novel and promising approach is combining VPA with other drugs to achieve a broad therapeutic index. Clinical studies are underway and the preliminary results indicate that VPA alone or in combination offers a promising avenue of treatment, both in solid and hematopoetic malignancies.
- Open Access
- 16 January 2003
- Published by Wiley in International Journal of Cancer
- Vol. 104 (1) , 36-43
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model
Cytotoxic drug treatment of neuroblastoma often leads to the development of drug resistance and may be associated with increased malignancy. To study the effects of long‐term cytotoxic treatment on malignant properties of tumor cells, we established 2 neuroblastoma cell sublines resistant to vincristine (VCR) and doxorubicin (DOX). Both established cell lines (UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100) were highly resistant to VCR, DOX and vice‐versa but retained their sensitivity to cisplatin. UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100 expressed significant amounts of P‐glycoprotein, while parental cells were P‐glycoprotein negative. GD2 expression was upregulated, whereas NCAM expression was decreased in both resistant cells. Spectral karyotype (SKY) analysis revealed complex aberrant karyotypes in all cell lines and additional acquired karyotype changes in both resistant cells. All cell lines harbored high levels of N‐myc amplification. Compared to parental cells, UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100 exhibited more than 2‐fold increase in clonal growth in vitro, accelerated adhesion and transendothelial penetration and higher tumorigenicity in vivo. We conclude that development of drug resistance and acquisition of certain karyotypic alterations is associated with an increase of additional malignant properties that may contribute to the poor prognosis in advanced forms of NB. The 2 novel neuroblastoma cell sublines also provide useful models for the study of drug resistance in aggressive forms of neuroblastoma.
- 16 January 2003
- Published by Wiley in International Journal of Cancer
- Vol. 104 (1) , 36-43
Open AccessDevelopment of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model
Cytotoxic drug treatment of neuroblastoma often leads to the development of drug resistance and may be associated with increased malignancy. To study the effects of long‐term cytotoxic treatment on malignant properties of tumor cells, we established 2 neuroblastoma cell sublines resistant to vincristine (VCR) and doxorubicin (DOX). Both established cell lines (UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100) were highly resistant to VCR, DOX and vice‐versa but retained their sensitivity to cisplatin. UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100 expressed significant amounts of P‐glycoprotein, while parental cells were P‐glycoprotein negative. GD2 expression was upregulated, whereas NCAM expression was decreased in both resistant cells. Spectral karyotype (SKY) analysis revealed complex aberrant karyotypes in all cell lines and additional acquired karyotype changes in both resistant cells. All cell lines harbored high levels of N‐myc amplification. Compared to parental cells, UKF‐NB‐2rVCR20 and UKF‐NB‐2rDOX100 exhibited more than 2‐fold increase in clonal growth in vitro, accelerated adhesion and transendothelial penetration and higher tumorigenicity in vivo. We conclude that development of drug resistance and acquisition of certain karyotypic alterations is associated with an increase of additional malignant properties that may contribute to the poor prognosis in advanced forms of NB. The 2 novel neuroblastoma cell sublines also provide useful models for the study of drug resistance in aggressive forms of neuroblastoma.
- 30 July 2002
- Published by Wiley in Medicinal Research Reviews
- Vol. 22 (5) , 492-511
Anti‐tumor mechanisms of valproate: A novel role for an old drug
Valproic acid (VPA, 2‐propylpentanoic acid) is an established drug in the long‐term therapy of epilepsy. During the past years, it has become evident that VPA is also associated with anti‐cancer activity. VPA not only suppresses tumor growth and metastasis, but also induces tumor differentiation in vitro and in vivo. Several modes of action might be relevant for the biological activity of VPA: (1) VPA increases the DNA binding of activating protein‐1 (AP‐1) transcription factor, and the expression of genes regulated by the extracellular‐regulated kinase (ERK)‐AP‐1 pathway; (2) VPA downregulates protein kinase C (PKC) activity; (3) VPA inhibits glycogen synthase kinase‐3β (GSK‐3β), a negative regulator of the Wnt signaling pathway; (4) VPA activates the peroxisome proliferator‐activated receptors PPARγ and †; (5) VPA blocks HDAC (histone deacetylase), causing hyperacetylation. The findings elucidate an important role of VPA for cancer therapy. VPA might also be useful as low toxicity agent given over long time periods for chemoprevention and/or for control of residual minimal disease. © 2002 Wiley Periodicals, Inc. Med Res Rev, 22, No. 5, 492–511, 2002; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.10017
- 30 July 2002
- Published by Wiley in Medicinal Research Reviews
- Vol. 22 (5) , 492-511
Anti‐tumor mechanisms of valproate: A novel role for an old drug
Valproic acid (VPA, 2‐propylpentanoic acid) is an established drug in the long‐term therapy of epilepsy. During the past years, it has become evident that VPA is also associated with anti‐cancer activity. VPA not only suppresses tumor growth and metastasis, but also induces tumor differentiation in vitro and in vivo. Several modes of action might be relevant for the biological activity of VPA: (1) VPA increases the DNA binding of activating protein‐1 (AP‐1) transcription factor, and the expression of genes regulated by the extracellular‐regulated kinase (ERK)‐AP‐1 pathway; (2) VPA downregulates protein kinase C (PKC) activity; (3) VPA inhibits glycogen synthase kinase‐3β (GSK‐3β), a negative regulator of the Wnt signaling pathway; (4) VPA activates the peroxisome proliferator‐activated receptors PPARγ and †; (5) VPA blocks HDAC (histone deacetylase), causing hyperacetylation. The findings elucidate an important role of VPA for cancer therapy. VPA might also be useful as low toxicity agent given over long time periods for chemoprevention and/or for control of residual minimal disease. © 2002 Wiley Periodicals, Inc. Med Res Rev, 22, No. 5, 492–511, 2002; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.10017
- 11 January 2000
- Published by Wiley in Journal of Medical Virology
- Vol. 60 (3) , 313-323
The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts
Human cytomegalovirus (HCMV) infection is associated with excessive proinflammatory immune responses such as cytokine/chemokine production or upregulation of adhesion molecules on the host cells. It is assumed that these features of HCMV‐related immunopathology can not be treated effectively with currently available anti HCMV drugs. In the present study the efficacy of ganciclovir (GCV), foscarnet (PFA), cidofovir (HPMPC), and ISIS 2922, an antisense oligonucleotide complementary to HCMV immediate‐early (IE) mRNA, was investigated on HCMV‐induced secretion and functional activity of the C‐X‐C chemokine IL‐8 and the expression of the intercellular adhesion molecule‐1 (ICAM‐1). As compared with mock‐infected cells IL‐8 production was increased up to 9‐fold and ICAM‐1 expression up to 4‐fold in HCMV‐infected fibroblasts. Treatment of infected cells with GCV (40 μM), PFA (200 μM) or HPMPC (2 μM) suppressed completely virus replication as demonstrated by quantification of late (L) antigen expression and infectious virus production. These drugs, however, failed to inhibit IE antigen expression and did not prevent HCMV‐induced upregulation of IL‐8 and ICAM‐1. In contrast, ISIS 2922 (1 μM) suppressed both IE and L antigen expression by 99% and inhibited infectious virus production by 104‐fold. Moreover, ISIS 2922 significantly suppressed HCMV‐induced upregulation of both IL‐8 and ICAM‐1 expression on the transcriptional and on the protein level. Our results indicate that ISIS 2922 but not inhibitors of HCMV DNA prevents HCMV‐induced upregulation of IL‐8 and ICAM‐1, both hallmarks of inflammatory processes. Thus, inhibition of HCMV IE expression with ISIS 2922 may be an important strategy for the treatment of HCMV‐related immunopathogenesis. J. Med. Virol. 60:313–323, 2000.
- 11 January 2000
- Published by Wiley in Journal of Medical Virology
- Vol. 60 (3) , 313-323
The antisense oligonucleotide ISIS 2922 prevents cytomegalovirus-induced upregulation of IL-8 and ICAM-1 in cultured human fibroblasts
Human cytomegalovirus (HCMV) infection is associated with excessive proinflammatory immune responses such as cytokine/chemokine production or upregulation of adhesion molecules on the host cells. It is assumed that these features of HCMV‐related immunopathology can not be treated effectively with currently available anti HCMV drugs. In the present study the efficacy of ganciclovir (GCV), foscarnet (PFA), cidofovir (HPMPC), and ISIS 2922, an antisense oligonucleotide complementary to HCMV immediate‐early (IE) mRNA, was investigated on HCMV‐induced secretion and functional activity of the C‐X‐C chemokine IL‐8 and the expression of the intercellular adhesion molecule‐1 (ICAM‐1). As compared with mock‐infected cells IL‐8 production was increased up to 9‐fold and ICAM‐1 expression up to 4‐fold in HCMV‐infected fibroblasts. Treatment of infected cells with GCV (40 μM), PFA (200 μM) or HPMPC (2 μM) suppressed completely virus replication as demonstrated by quantification of late (L) antigen expression and infectious virus production. These drugs, however, failed to inhibit IE antigen expression and did not prevent HCMV‐induced upregulation of IL‐8 and ICAM‐1. In contrast, ISIS 2922 (1 μM) suppressed both IE and L antigen expression by 99% and inhibited infectious virus production by 104‐fold. Moreover, ISIS 2922 significantly suppressed HCMV‐induced upregulation of both IL‐8 and ICAM‐1 expression on the transcriptional and on the protein level. Our results indicate that ISIS 2922 but not inhibitors of HCMV DNA prevents HCMV‐induced upregulation of IL‐8 and ICAM‐1, both hallmarks of inflammatory processes. Thus, inhibition of HCMV IE expression with ISIS 2922 may be an important strategy for the treatment of HCMV‐related immunopathogenesis. J. Med. Virol. 60:313–323, 2000.